MREO: Class Action Filed, Investors Urged to Act Now!

Company Overview and Recent Developments

Mereo BioPharma Group plc (NASDAQ: MREO) is a U.K.-based clinical-stage biopharmaceutical company focused on rare diseases, with lead programs in osteogenesis imperfecta (OI, brittle bone disease) and alpha-1 antitrypsin deficiency lung disease (www.mereobiopharma.com) (www.mereobiopharma.com). The company’s fortunes took a sharp turn on December 29, 2025, when its pivotal Phase 3 trials (ORBIT and COSMIC) for the OI drug setrusumab (UX143) failed to meet primary endpoints (www.mereobiopharma.com). While the studies showed improved bone density, neither achieved a statistically significant reduction in fracture rates compared to placebo or standard care (www.mereobiopharma.com) (www.mereobiopharma.com). Following this news, Mereo’s American Depositary Shares (ADS) collapsed ~88% in a single day, plunging from $2.31 to $0.29 (www.globenewswire.com). This catastrophic loss of shareholder value triggered multiple shareholder class-action lawsuits alleging that Mereo’s executives misled investors with overly positive statements about setrusumab’s prospects while concealing adverse facts (www.globenewswire.com) (www.ainvest.com). The legal complaints cite management’s expressed “confidence” in setrusumab’s ability to reduce fractures and hit trial endpoints, even as internal data suggested otherwise (www.prnewswire.com) (www.prnewswire.com). With an April 6, 2026 lead plaintiff deadline looming for investors to join the class action (www.globenewswire.com) (www.prnewswire.com), Mereo now faces both a scientific setback and a legal/credibility crisis. Below we examine the company’s dividend policy, financial leverage, valuation, and the key risks and uncertainties going forward in the wake of these developments.

Dividend Policy and Yield

Mereo has never paid any dividend on its ordinary shares and does not anticipate doing so in the foreseeable future (www.sec.gov). As a clinical-stage biotech with no product revenues, the company’s policy is to retain all capital to fund R&D and operations rather than return cash to shareholders (www.sec.gov). In fact, under U.K. law Mereo cannot pay dividends until it has distributable profits, which it currently lacks due to accumulated losses (www.sec.gov). Consequently, MREO’s dividend yield is 0%, and income-focused investors have never been part of the shareholder base. Traditional REIT metrics like FFO or AFFO are not applicable here – Mereo generates no operating cash flow (it reported a net loss of ~$41.9 million in 2025) (www.mereobiopharma.com) and instead relies on cash reserves and periodic fundraising to finance its drug development. Investors should not expect any dividends for the foreseeable future, as the company will prioritize advancing its pipeline and preserving cash.

Leverage, Debt Maturities, and Coverage

Despite its challenges, Mereo’s balance sheet carries minimal debt. The company had issued convertible loan notes in prior years (including a £3.8 million note to Novartis in 2020), but as of year-end 2025 these have effectively been eliminated (www.mereobiopharma.com). Mereo amended and then fully repaid or converted its convertible notes by early 2025, leaving no convertible debt outstanding at December 31, 2025 (www.mereobiopharma.com). (At the end of 2024, $5.5 million in notes were classified as current liabilities, but by end of 2025 this line was zero (www.mereobiopharma.com).) This means Mereo is now essentially debt-free, with only routine payables and lease obligations on its books. Total liabilities were just $5.0 million at 2025 year-end, down from $15.4 million a year prior (www.mereobiopharma.com).

With cash and equivalents of $41.0 million on hand as of December 31, 2025 (www.mereobiopharma.com), Mereo has a net cash position and no bank debt to service. As a result, metrics like interest coverage are not meaningful – the company’s interest income from its cash holdings actually exceeded any interest expense in 2025 (www.mereobiopharma.com). Mereo’s cash runway is projected into mid-2027 after management enacted cost-cutting and halted pre-commercial manufacturing spend for setrusumab (www.mereobiopharma.com) (www.mereobiopharma.com). This runway guidance assumes no new revenue and no major trials initiated without partner funding. It’s important to note that the viability of this plan depends on tight cost control; Mereo dramatically reduced its operating burn rate after the trial failure. The company is actively seeking a partner to fund its next Phase 3 program (for alvelestat – see below), which, if secured, could further extend the cash runway or provide upfront capital. In summary, leverage is very low and near-term debt maturity risk is off the table, but Mereo’s long-term solvency still hinges on its ability to extract value from the pipeline before the cash runs out.

Valuation and Comparable Metrics

Traditional valuation metrics are difficult to apply to Mereo, given its lack of earnings and revenue. The company’s value is mostly tied to its cash balance and pipeline optionality. After the stock crash, MREO shares have been trading in mere cents – recently around $0.33 per ADS in late March 2026 (www.ainvest.com). Each Nasdaq-traded ADS represents five ordinary shares, and there were ~159.1 million ADS-equivalent shares outstanding at year-end (www.mereobiopharma.com). At a ~$0.33 market price, Mereo’s market capitalization is only about $52–53 million, which is only slightly above its last reported cash of $41 million. In other words, the market is currently valuing all of Mereo’s drug pipeline and other assets at roughly $10–12 million (enterprise value), indicating extreme skepticism about the company’s ability to create future value. By comparison, prior to the trial failure, Mereo’s market cap was on the order of $300+ million (when the stock traded above $2.30 (www.globenewswire.com)). The 87% collapse in share price essentially wiped out over $250 million in market value (www.globenewswire.com), reflecting investors’ perception that setrusumab’s failure leaves the company with a much dimmer outlook.

Because Mereo has no positive EBITDA or FFO, valuation can’t be assessed by P/E or P/FFO ratios (these are negative or not meaningful). Another lens is price-to-book (P/B): as of Dec 2025, shareholders’ equity was ~$40.9 million (www.mereobiopharma.com), so the stock currently trades at roughly 1.3 times book value. However, that book value consists mostly of cash; the company’s “pipeline value” appears deeply discounted by the market. It’s common for distressed biotechs to trade near or below net cash when confidence in the pipeline is very low. Mereo’s valuation is now similar to a shell or an option value on its remaining assets. Any future upside in the stock would likely hinge on favorable developments – for instance, a partnership deal, a regulatory breakthrough, or new data that resurrects some hope for setrusumab or other programs. Conversely, the stock could languish or fall further if the company merely burns cash with no progress. (Notably, at ~$0.33, MREO also risks non-compliance with Nasdaq’s $1 minimum bid price rule if that price persists, raising the prospect of a reverse split down the line – a common occurrence for micro-cap biotechs in this situation.)

Key Risks and Red Flags

Mereo’s situation entails significant risks and several red flags that investors should weigh carefully:

– Clinical Failure of the Lead Asset: The most obvious risk is that setrusumab may never become a viable product. The Phase 3 failure in OI is a major blow – this was Mereo’s flagship program and the rationale for a lucrative partnership with Ultragenyx. Without meeting primary endpoints (fracture reduction), the path to regulatory approval is unclear. Management noted that they are conducting further analyses and identified some positive trends in bone density and reduced vertebral fractures in subgroups (www.mereobiopharma.com) (www.mereobiopharma.com). They believe these post-hoc analyses might form the basis of discussions with regulators (www.mereobiopharma.com). However, it is far from guaranteed that regulators will accept secondary endpoints or subgroup data in lieu of a successful Phase 3. The risk of complete failure of setrusumab is real – if no viable pathway is found, the $245 million in potential Ultragenyx milestone payments will never materialize (www.mereobiopharma.com), and Mereo’s years of effort on this asset will result in no return. This puts enormous pressure on the rest of the pipeline (especially alvelestat) to deliver value.

– Legal and Credibility Overhang: The securities class action now underway is itself a risk factor. Beyond potential monetary damages or legal costs (often covered by D&O insurance), the lawsuit’s allegations of misleading investors cast doubt on management’s credibility (www.ainvest.com). The complaint specifically claims Mereo’s executives talked up setrusumab’s prospects – expressing confidence it would reduce fracture rates and hit its endpoint – while “concealing material adverse facts” about the true trial outlook (www.ainvest.com) (www.prnewswire.com). If evidence emerges to support these claims (e.g. knowledge of negative interim data that was kept quiet), it would be a serious red flag on corporate governance. Even if the case is settled, it may reinforce investor distrust. The situation also diverts management attention at a critical time. Overall, the reputational damage from the trial failure and lawsuit could make it harder for Mereo to raise capital or strike partnerships, as partners will do extra diligence on the company’s transparency and management.

– Insider Stock Sales: Another red flag is the pattern of insider selling prior to the trial failure. SEC filings show that multiple insiders sold shares in recent years, including the CEO. In late June 2024, CEO Dr. Denise Scots-Knight sold about 132,985 ADS (equivalent to ~664,925 ordinary shares) at an average ~$3.40–$3.69, netting roughly $463,000 (www.investing.com) (www.investing.com). She sold another ~88,657 ADS in September 2024 at ~$4.22–$4.47 for about $381,000 (www.investing.com). In total, over a three-year span insiders have sold approximately $1.28 million worth of stock (www.ainvest.com). The company states these sales were part of “sell-to-cover” transactions to pay taxes on vested restricted shares (and thus were not discretionary open-market sales) (www.investing.com). Nevertheless, the lack of any significant insider buying – even after the price collapsed – raises concern. Insiders reducing their holdings (even for planned reasons) right before a pivotal readout can appear suspicious to investors in hindsight. Now with shares near 30 cents, no insiders have stepped up to buy on the open market, which might indicate a lack of confidence in the turnaround. This “skin in the game” concern, combined with the lawsuit, may lead shareholders to question management’s alignment with their interests.

– Dilution and Financing Risk: Mereo’s cash runway is finite (mid-2027 under current plans) (www.mereobiopharma.com). If the company fails to secure a partnership or other non-dilutive funding, it may eventually need to raise capital by issuing equity. Given the current low share price, any new equity raise would be highly dilutive to existing shareholders. For context, Mereo has already expanded its share count substantially via prior financings – nearly 800 million ordinary shares are outstanding (159 million ADS) (www.mereobiopharma.com), up from ~701 million at the end of 2023 (media.mereobiopharma.com). The potential for further dilution is a serious risk to remaining shareholders. Additionally, maintaining a U.S. listing could necessitate measures like a reverse stock split if the share price stays below $1 for an extended period – which, while cosmetic, can sometimes erode value further if it signals distress.

– Pipeline Concentration and Execution: With setrusumab’s outcome uncertain, Mereo’s fate hinges largely on its other programs, chiefly alvelestat for alpha-1 antitrypsin deficiency (AATD) lung disease. Alvelestat has shown promise in Phase 2 but still requires a lengthy and costly Phase 3 trial (estimated ~220 patients over 18 months) (www.mereobiopharma.com). Mereo has wisely held off starting this trial until it finds a development/commercial partner to share the cost (www.mereobiopharma.com) (www.mereobiopharma.com). If no partner comes forward, alvelestat’s Phase 3 could be delayed indefinitely – or attempted solo, which would burn most of Mereo’s cash and still might fail. This binary dependence on partnering is a risk; the timing and terms of any deal are uncertain, and Mereo’s bargaining position may be weakened post-setrusumab. Furthermore, any clinical hiccups with alvelestat or other earlier-stage assets (like the oncology compounds out-licensed to others) would leave the company with very few alternatives. In short, Mereo is a high-risk bet on a couple of niche programs, in a tough funding environment.

In aggregate, these factors paint a picture of a company in a precarious position. Mereo’s risk profile is extremely elevated: it faces scientific risk (needing to salvage a failed program), legal risk (class action), financial risk (limited cash and dilution potential), and leadership/credibility risk – all at once. Investors are urged to perform thorough due diligence and risk assessment, especially in light of the class action allegations and the steep erosion of shareholder value.

Open Questions and Outlook

Looking ahead, several critical questions remain open for Mereo BioPharma:

– Can setrusumab be salvaged in any form? Management insists that additional analyses of the Phase 3 data (e.g. in younger pediatric subgroups, vertebral fracture outcomes, and patient-reported measures) could support engagement with regulators (www.mereobiopharma.com) (www.mereobiopharma.com). It is possible regulators might consider a very narrow approval or require another trial. One open question is whether Mereo and partner Ultragenyx will pursue a new trial or regulatory filing despite the failed endpoints. Ultragenyx’s stance is crucial – will it continue funding any further OI development or was this effectively the end? Clarity on setrusumab’s fate (abandon, new trial, or attempt an approval on surrogate endpoints) is eagerly awaited. Any update in 2026 on discussions with the FDA/EMA will be a major catalyst for the stock, either positive or negative.

– What will happen with the Ultragenyx partnership? Under the deal, Ultragenyx was leading and funding the setrusumab trials (www.mereobiopharma.com). If Ultragenyx deems the program no longer viable, they could walk away, leaving Mereo with EU/UK rights to a shelved drug. Alternatively, Ultragenyx might negotiate new terms or shift strategy (for example, focusing on an observational study or a different patient population). Investors will be watching for signals from Ultragenyx (which is a well-capitalized rare disease pharma) – their continued involvement (or lack thereof) will heavily influence Mereo’s prospects. The $245 million in potential milestones and future royalties announced for this partnership (www.mereobiopharma.com) now look very uncertain; an open question is whether any portion of those milestones (for instance, an EU approval filing) can still be earned or if they’re off the table.

– Can Mereo secure a partner for alvelestat, and when? With setrusumab sidelined, alvelestat (MPH-966) becomes the key value driver. The company has said it is in active discussions with multiple potential partners to co-develop and commercialize alvelestat (www.mereobiopharma.com). The goal is to have a partner fund or support the Phase 3 trial for AATD lung disease, which is planned as a single pivotal study (~220 patients, 18-month treatment) agreed upon with regulators (www.mereobiopharma.com) (www.mereobiopharma.com). A big question is when (and if) Mereo can strike a partnership deal. A timely deal could bring in an upfront payment (extending the cash runway) and validate the drug’s prospects. No deal, on the other hand, might force Mereo to either shelve alvelestat or attempt a trial on its own (which seems infeasible financially at this point). This uncertainty likely keeps pressure on the stock. Any announcement regarding alvelestat partnering will be a make-or-break moment for the company’s medium-term outlook.

– How will the class action be resolved? The outcome of the investor lawsuit is another unknown. Will Mereo fight the allegations or move to settle? The lead plaintiff deadline (April 6, 2026) has just passed (www.globenewswire.com), so the case will proceed with a representative shareholder. If damning internal evidence emerges during discovery, it could further tarnish Mereo’s management or force corporate changes. A settlement could also use up some cash (though typically insurance covers much). Investors will want to see if any governance or leadership changes occur – for example, does Mereo add new independent directors, or does the CEO retain the confidence of the board after the trial failure and lawsuit? How the company handles accountability will influence investor sentiment. This open question ties into the broader issue of trust: Mereo must convince the market that it is being fully transparent going forward.

– Are strategic alternatives on the table? With its stock at a fraction of past levels, one might ask if Mereo could become a takeover or merger candidate. For instance, another biotech or pharma company interested in alvelestat or Mereo’s other assets might consider acquiring the company outright (especially given its low enterprise value). Alternatively, Mereo could seek a reverse merger with a private company that has funding (a path some struggling biotechs take to survive). There have been no public signals of such moves, but as an open question, investors should watch for any activism or strategic review. Management’s focus so far is on continuing operations independently, but this could change if the status quo doesn’t improve.

In conclusion, Mereo faces an uphill battle to rebuild value after the setrusumab setback. The next few quarters will be critical in answering these open questions. Positive developments – such as a partnership deal or encouraging regulatory feedback – could stabilize the company and provide a foundation for recovery. However, absent such catalysts, the stock may continue to drift given the overhang of the class action and the palpable investor skepticism (the stock’s trading near cash value indicates low expectations). Current and prospective shareholders should closely monitor news flow from the company, including any scientific updates, partnership announcements, or legal/regulatory disclosures. Until there is more clarity on how management will navigate this crisis, and whether the remaining pipeline can deliver, MREO remains a speculative situation with high risk. Investors are urged to act cautiously and ensure they are informed of their rights (in the case of those who incurred losses during the class period) (www.globenewswire.com) and of all the evolving developments around this company.

Sources: Key information in this report is sourced from Mereo’s official filings and press releases, as well as credible financial news outlets. Notable references include the company’s December 29, 2025 announcement of the Phase 3 results (www.mereobiopharma.com), its March 19, 2026 full-year financial results update (www.mereobiopharma.com) (www.mereobiopharma.com), and class action notices from law firms (e.g. Gross Law and Rosen Law) outlining the lawsuit allegations and stock drop details (www.globenewswire.com) (www.globenewswire.com). Additional insights on insider trading were obtained from SEC filings summarized by Investing.com (www.investing.com) (www.investing.com). These and other inline citations provide the factual backbone for the analysis above.

For informational purposes only; not investment advice.